Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
Dollar change
Percentage change
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-7.77% Shs Outstand Perf Week-4.70%
SponsorBlackrock (iShares) ETF Type Tagsequity Return% 3Y-20.93% Total Holdings64 Perf Month-6.95%
Fund Family Bond Type Tagshealthcare Return% 5Y- AUM129.97M Perf Quarter-1.60%
IndexNYSE FactSet Global Genomics and Immuno... Average Maturity Tagsgenomics Return% 10Y NAV% Perf Half Y14.34%
Index Weighting Commodity Type Tagspharmaceutical Return% SI NAV/sh Perf Year-9.80%
Active/Passive Quant Type Tagsinnovation Flows% 1M-1.82% 52W Range17.33 - 25.52 Perf YTD-4.00%
Dividend TTM0.24 (1.09%) ESG Type Tags- Flows% 3M6.64% 52W High-13.43% Beta0.99
Dividend Ex-DateDec 20, 2023 Dividend Type Sector/Theme Flows% YTD1.68% 52W Low27.47% ATR (14)0.40
Expense0.47% Structure Type Region Flows% 1Y RSI (14)30.26 Volatility1.81% 1.52%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.50 Prev Close22.20
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume44.42K Price22.09
SMA20-5.77% SMA50-6.49% SMA2000.20% Trades Volume22,097 Change-0.50%
Sep-09-22 01:45PM
Mar-30-22 01:30PM
Feb-25-22 09:59PM
Dec-06-21 10:15AM
Oct-21-21 10:15AM
03:42PM Loading…
May-18-20 03:42PM
Dec-23-19 12:00PM
Dec-18-19 01:41PM
Nov-25-19 06:55PM
Nov-21-19 12:56PM
Nov-04-19 01:00PM
Oct-23-19 10:10AM
Sep-06-19 03:07PM
Sep-04-19 03:18PM
iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.